Exanthem

Summary

Exanthem (MONDO:0006547) is a disease (an umbrella term covering 13 Mondo subtypes) and 20 clinical trials. Top therapeutic interventions include clindamycin, fexofenadine, and acitretin. A subtype of skin disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 13 Mondo subtypes
• Clinical trials: 20

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	exanthem
Mondo ID	MONDO:0006547
EFO	EFO:1000697
MeSH	D005076
DOID	DOID:0050486
SNOMED CT	271807003
UMLS	C0015230
MedGen	8732
Is cancer (heuristic)	no

Also known as: cutaneous eruption · exanthem · exanthem (disease) · exanthema · rash · skin eruption · skin rash

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of skin disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › exanthem

Related subtypes (71): dermatitis, cutaneous mucinosis, skin neoplasm, pyoderma, chronic ulcer of skin, systemic sclerosis, sunburn, severe cutaneous adverse reaction, paronychia, Achenbach syndrome, erythema multiforme, erythematosquamous dermatosis, facial dermatosis, hand dermatosis, keratosis, leg dermatosis, lichen disease, lipodystrophy, mongolian spot, reactive cutaneous fibrous lesion, rosacea, scalp dermatosis, sebaceous gland disorder, skin atrophy, skin sarcoidosis, sweat gland disorder, vesiculobullous skin disease, hyperglobulinemic purpura, ainhum, cheilitis glandularis, erythema palmare hereditarium, multiple benign circumferential skin creases on limbs, actinic prurigo, congenital lethal erythroderma, Parana hard-skin syndrome, Bazex-Dupre-Christol syndrome, nephrogenic systemic fibrosis, erosive pustular dermatosis of the scalp, pseudoxanthoma elasticum-like papillary dermal elastolysis, toxic dermatosis, oral erosive lichen, chronic actinic dermatitis, Jessner lymphocytic infiltration of the skin, acquired kinky hair syndrome, primary cutaneous plasmacytosis, cutaneous pseudolymphoma, corticosteroid-sensitive aseptic abscess syndrome, interstitial granulomatous dermatitis with arthritis, epidermal disease, skin pigmentation disorder, skin vascular disease, Wells syndrome, solar urticaria, pellagra, hereditary epidermal appendage anomaly, keratosis pilaris, dermis disorder, aquagenic pruritus, Boudhina Yedes Khiari syndrome, non-neoplastic nevus, cutaneous sclerosis, pityriasis rotunda, hematohidrosis, skin disorder caused by infection, livedoid vasculopathy, prurigo nodularis, granuloma faciale, sclerema neonatorum, hereditary skin disorder, hand-foot syndrome, Nicolau syndrome

Subtypes (13): exanthema subitum, variola major infectious disease, pityriasis versicolor, bacterial exanthem, pityriasis rosea, viral exanthem, prurigo, pityriasis lichenoides, pityriasis simplex, pityriasis folliculorum, pityriasis amiantacea, pityriasis alba, pityriasis steatoides

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Hydrocortisone	Approved (phase 4)
Zinc Oxide	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 20.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	9
PHASE2	7
PHASE1	2
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01299220	PHASE4	WITHDRAWN	Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)
NCT01136005	PHASE3	COMPLETED	Bepanthen Versus Cetomacrogol in Epidermal Growth Factor Receptor Inhibitors (EGFRI)
NCT06399029	PHASE2	ACTIVE_NOT_RECRUITING	Topical Ruxolitinib Evaluation in Immune-related Lichenoid Skin-Toxicities
NCT00332163	PHASE2	COMPLETED	Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
NCT00343187	PHASE2	TERMINATED	A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash
NCT00473083	PHASE2	COMPLETED	Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer
NCT00667589	PHASE2	TERMINATED	Sorafenib-induced Hand- Foot Skin Reaction Treatment
NCT01692626	PHASE2	TERMINATED	1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX
NCT01880515	PHASE2	COMPLETED	Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib)
NCT02326467	PHASE1	COMPLETED	Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age
NCT05461456	PHASE1	COMPLETED	Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
NCT06560853	Not specified	ACTIVE_NOT_RECRUITING	Evaluation of a Comprehensive School Health Programme in Zambia
NCT07112846	Not specified	NOT_YET_RECRUITING	Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections
NCT07476807	Not specified	ENROLLING_BY_INVITATION	Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study
NCT00610818	Not specified	TERMINATED	Effect of Palifermin on Skin Tumors in Patients Undergoing Bone Marrow Transplantation
NCT00709878	Not specified	COMPLETED	Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors
NCT01339546	Not specified	COMPLETED	National Trends in Otitis Media in Children Under 5 Years of Age
NCT03102905	Not specified	UNKNOWN	Prevalence of Replication of Human Herpes Virus 6 (HHV6) in Blood and Skin During Exanthemia, in Patients With Hemopathy. Is There a Correlation With the Etiology of the Exanthema?
NCT05247333	Not specified	COMPLETED	Implementation of a Minor Ailment Service in Community Pharmacy Practice
NCT06755424	Not specified	COMPLETED	GI Symptoms in Infants Fed Goat Milk-based Infant Formula

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CLINDAMYCIN	4	3
FEXOFENADINE	4	3
ACITRETIN	4	1
CHLORHEXIDINE GLUCONATE	4	1
DEXPANTHENOL	4	1
FLUOCINONIDE	4	1
MINOCYCLINE	4	1
PALIFERMIN	4	1
PANITUMUMAB	4	1
PIMECROLIMUS	4	1
TAZAROTENE	4	1
TETRACYCLINE	4	1
UREA	4	1
CHEMBL3775171	0	1
CHEMBL4630645	0	1
CHEMBL1628	0	1